Hypertension
Conditions
Interventions
For 8 weeks prior to observation period: azilsartan 20 mg, Ca antagonist To 48 weeks: sacubitril/valsartan 200 mg, Ca antagonist From 8 weeks to 48 weeks: increase, decrease, or discontinue Ca antag
Sponsors
Tachibanadai clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with essential hypertension with a systolic home systolic blood pressure of 135 mmHg or higher despite treatment with azilsartan 20 mg and Ca antagonist for at least 8 weeks. 2. Any age 3. Any gender 4. Patients who have never taken sacubitril/valsartan before 5. Outpatients 6. Patients who have given written informed consent to participate in the study.
Exclusion criteria
Exclusion criteria: 1. Patients with secondary hypertension 2. Patients in non-sinus rhythm or with a history of atrial fibrillation 3. Patients under treatment for heart failure, plasma BNP level >=100 pg/mL, or with a history of heart failure 4. Patients with eGFR <30mL/min/1.73m2
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Home systolic and diastolic blood pressure at baseline, 8 weeks, 24 weeks and 48 weeks after the switch. | — |
Secondary
| Measure | Time frame |
|---|---|
| The rate of achieving the target blood pressure. The change of pulse rate. The change of laboratory test results, including as plasma BNP level, serum creatinine level, eGFR, serum potassium level, serum uric acid level, HbA1c. | — |
Countries
Japan
Contacts
Public ContactTsugiyoshi Yamazaki
Tachibanadai clinic Department of Cardiology
Outcome results
None listed